Manager Development

Dwayne C. Ford

**** ****** ****** **

Atlanta GA 30331

Home 770-***-****

E-mail: ******@**.***

Citizenship: USA

EDUCATION

Brown University, Providence, RI

Bachelor of Arts in Biology

Johnson & Wales University, Providence, RI

A.A.S. Culinary Arts Summa Cum Laude

PROFESSIONAL EXPERIENCE

4/11 - Present Chef Dee’s Famous Cheesecakes

Atlanta, GA

Executive Chef

4/08-3/11 Senior Lab Manager

University of Miami

Miller School of Medicine

Dermatology/Stem Cell Institute

• Managed and trained medical, graduate and undergraduate students in

current laboratory SOP’s, practices and translational research theories for

integration into daily operations and personal career development.

• Participated in overall institutional facilities management and

equipment operational controls to ensure proper utilization and protection of

major capital equipment purchases.

• Procured new fluorescent confocal microscopy analytical equipment

for high end data acquisition and trained staff on image acquisition and

proper data arithmetical operations and techniques.

• Trained and certified in FDA compliant cGMP facility operations

including the processing and harvesting of patient material for application

and delivery in FDA approved Phase I Clinical Trials.

Page 1 of 7

• Contributed to development of FDA /IND applications for submission

with subsequent approvals for Phase I clinical trials.

Experienced with pre IND FDA conferences, question and answer

•

sessions as well as proper filing with the FDA of yearly modification and

progress reports.

Responsible for writing and revising Laboratory Standard Operating

•

Procedures/Level III Documents (SOPs) Master Batch Records (MBR),

Change Controls (CCs) and Deviation Reports (DR).

• Isolated primary cultures from patient tissues for in vitro assessment

and comparison with clinical trial outcomes and results.

• Developed, maintained and genetically modified various stem cell

populations of human, porcine and murine origin including mesenchymal,

neural, lineage negative, hematopoetic and Dexter culture derived

heterogeneous cells for potential therapeutic and novel clinical trials.

• Performed functional analysis of stem cell populations to verify

integrity of isolation and culturing methods for maintaining stem cell

characteristics.

• Developed current methodology for obtaining and propagating various

stem cell populations from initial isolation to cell maintenance including

hypoxia and hypothermal environments.

• Responsible for filing and maintaining all institutional reviewable

documents including animal care (IACUC) and Institutional Biosafety

Committee (IBC) for compliance with ethical and safety concerns.

Utilized five and nine multicolor FACS sorting and analysis to isolate

•

and characterize rare populations of stem cells for pre clinical assessment prior

to IND application for clinical trial approval.

Skilled in developing, modifying and optimizing lentiviral gene delivery

•

systems to transduce stem cells, primary, non dividing or difficult to transfect

cells with novel and various fluorescent markers or other genes of interest.

Engineered novel fluorescent lentiviral vector fusion constructs,

•

bicistronic and promoter specific constructs for innovative cell tracking and

differentiation research projects in porcine and murine transplant models.

Competent in laboratory budget and resource management including

•

ARIBA (ordering) and DMAS (departmental management accounting

software.

Page 2 of 7

Capable of performing independent and creative research project

•

development for departmental and collaborative efforts utilizing up to date and

cutting edge technologies.

Experienced in managing multiple collaborative efforts in the

•

multidisciplinary arenas of stem cell research geared towards the development

of new and innovative clinical trials.

Participated in and lead independent development of new laboratory

•

directions and techniques including design and implementation of new

protocols.

Knowledge in scientific manuscript and grant writing, preparation and

•

editing including graphics, narrative and layout.

11/93-1/08 Research Assistant IV

Lab Supervisor/Manager

University Medical Group

Roger Williams Medical Center, Providence RI

Immunology/Pathology Research Laboratory

C.O.B.R.E (Center Of Biological Research Excellence)

• IND application submission with approval for Phase I clinical trial

• Provided preliminary data, scientific technology and methodology for

successful RO1 grant submission and funding.

• Modified and optimized a lentiviral gene delivery system to transduce

primary, non-dividing or difficult to transfect cells with various fluorescent

markers or other genes of interest.

• Engineered novel fluorescent lentiviral vector fusion contructs for

innovative cell tracking research projects to circumvent inherent “leaky”

soluble GFP issues as well as provide novel methods for cell fusion studies.

• qRT-PCR assay development for lentiviral titration, characterization

and analysis at the vRNA, mRNA and integrated DNA levels.

• Collaborated in the development of SOP’s for hNSC (human Neural

Stem Cell) maintenance, viral transduction and differentiation with

subsequent IHC (ImmunoHistoChemical) analysis.

• Successfully cloned zinc finger transcription factors of the SALL

family by restriction fragment cloning.

• Transient transfection of SALL proteins with subsequent analysis by

GST pull-down and Western blot utilizing novel peptide and native protein

polyclonal antibodies.

Page 3 of 7

• Developed an efficient system for high level production and

purification of novel native mammalian proteins for downstream applications

(e.g. antibody production)

• Mutational and deletional analyses of SALL proteins.

• Supervised and trained college, medical students and residents working

on independent laboratory projects for communication and submission to

Chief of Pathology.

• Researched and implemented new projects including global

collaborative efforts.

• Successfully cloned, produced and purified a recombinant, biologically

active mutant form of IL-13, [Phe43] IL-13 gygy.

• Characterized and expressed the IL-4 and IL-13 binding receptors in

various cells using Transfection, Western, Scatchard, and 125I-IL-4, 125I-IL-13

and 125I-[Phe43] IL-13gygy competition assays.

• Analyzed signal transduction components of the IL-4 and IL-13

receptors.

• Produced quantitative assays using competitive RT-PCR technique.

• Developed protocols and implemented production and utilization of a

novel, cell-free vaccine in a murine melanoma model.

• Facilitated in the production and development of a new FDA filed

Cancer drug.

• Developed protocols for separation of PBMC subset populations (i.e.

+ + +

CD3, CD19, CD14 ) from buffy coat or peripheral blood cells using

panning, rosetting, magnetic and antibody/complement-mediated cytotoxicity

techniques.

• Utilized FLOW CYTOMETRY to characterize cell populations,

receptor/ligand expression and cell cycle analysis.

• Characterized various cytokines (i.e. IL-2,IL-4,IL-13) and antibodies

(anti-Mu, and anti-CD40) and their effect on B cell (CD19+) activation and

growth.

• Quantified cell proliferation using Tritiated Thymidine Incorporation.

• Studied the effect of Taxol on PBMC and their expression of cell

surface molecules.

• Developed murine model to study the effect of L-Carnitine on

S.typhimurium induced sepsis and produced a detailed 75-page report.

• Analyzed Cytokines and Eicosanoids using ELISA technique.

• Murine splenic lymphocyte preparation ; murine blood collection using

cardiac puncture technique and murine tissue collection for histological

examination.

Page 4 of 7

SPECIAL SKILLS, REGULATORY EXPERIENCE AND QUALIFICATIONS

- FDA (Food and Drug Administration) IND (Investigational New Drug) application

submission with subsequent approval for Phase I clinical trials. SOP (Standard Operating

Procedures) creation for Phase I clinical trial with Deviation Report experience for protocol

amendments and development. cGMP qualified and certified technician status.

- Experience in the processing, maintenance and collection of human tissues designated for

delivery to patients under cGMP and GLP conditions.

- Experimental design and preliminary data production for successful NIH RO1 grant

submission.

- CITI Certified since 2008.

- Strong leadership qualities with 18 years experience in lab supervision and student training.

- Experience in laboratory budget and resource management.

- Proficient use of past scientific knowledge in comprehending new techniques. Independent

in development of new laboratory directions and techniques including design and

implementation of new protocols.

- Enthusiastic and experienced in synergistic collaborative efforts in the arenas of stem cell

research with a high correlation to translational research for implementation of new clinical

trials.

- Scientific manuscript writing and preparation.

- Proficient in interacting with the public and colleagues.

PUBLICATIONS

• Rodriguez-Menocal L, Salgado M, Ford D, Van Badiavas E.

Page 5 of 7

Stimulation of Skin and Wound Fibroblast Migration by Mesenchymal Stem

Cells Derived from Normal Donors and Chronic Wound Patients. Stem Cells

Translational Medicine 2012; 1:221-9.

• Badiavas EV, Ford D, Liu P, Kouttab N, Morgan J, Richards A,

Maizel A. Long term bone marrow culture and its clinical potential in

chronic wound healing. Wound Rep. Reg 2007 Oct/Nov 15(6) 856-865

• Roy B, Bhattacharjee A, Xu B, Ford D, Maizel AL, Cathcart MK.

IL-13 signal transduction in human monocytes: phosphorylation of receptor

components, association with Jaks, and phosphorylation/activation of Stats.

J Leukoc Biol. 2002 Sep;72(3):580-9.

• Ma Y, Chai L, Cortez SC, Stopa EG, Steinhoff MM, Ford D,

Morgan J, Maizel AL. SALL1 expression in the human pituitary-

adrenal/gonadal axis.

J Endocrinol. 2002 Jun;173(3):437-48.

• David M, Ford D, Bertoglio J, Maizel AL, Pierre J.

Induction of the IL-13 receptor alpha2-chain by IL-4 and Il-13 in human

keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways.

Oncogene. 2001 Oct 11;20(46):6660-8.

• Ma Y, Li D, Chai L, Luciani AM, Ford D, Morgan J, Maizel AL.

Cloning and characterization of two promoters for the human HSAL2 gene

and their transcriptional repression by the Wilms tumor suppressor gene

product.

J Biol Chem. 2001 Dec 21;276(51):48223-30

• Ma Y, Singer DB, Gozman A, Ford D, Chai L, Steinhoff MM,

Hansen K Maizel AL

Hsal 1 is related to kidney and gonad development and is expressed in Wilms

tumor. Pediatr Nephrol. 2001 Sep; 16 (9):701-9

Page 6 of 7

• Morgan JW, Kouttab N, Ford D, Maizel AL.

Vitamin D-mediated gene regulation in phenotypically defined human B cell

subpopulations. Endocrinology. 2000 Sep;141(9):3225-34.

• Ford D, Sheehan C, Girasole C, Priester R, Kouttab N, Tigges J,

King TC, Luciani A, Morgan JW, Maizel AL.

The human B cell response to IL-13 is dependent on cellular phenotype as

well as mode of activation. J. Immunology 1999 Sep 15;163(6):3185-93.

• Ogata H, Ford D, Kouttab N, King TC, Vita N, Minty A, Stoeckler

J, Morgan D, Girasole C, Morgan JW, Maizel AL.

Regulation of interleukin-13 receptor constituents on mature human B-

lymphocytes. J. Biological Chemistry 1998 Apr 17;273(16):9864-71.

• Morgan JW, Morgan DM, Lasky SR, Ford D, Kouttab N, Maizel

AL.

Requirements for induction of vitamin D-mediated gene regulation in normal

human B-lymphocytes. J. Immunology 1996 Oct 1;157(7):2900-8.

• Morgan JW, Morgan DM, Lasky SR, Ford D, Kouttab N, Maizel

AL.

Requirements for induction of vitamin D-mediated gene regulation in normal

human B-lymphocytes. J. Immunology 1996 Oct 1;157(7):2900-8.

COMMUNITY ACTIVITIES

Vice President/Executive Board Member Christine’s Kitchen Incorporated

501c (3) www.christineskitchen.org

REFERENCES

Available upon Request

Page 7 of 7

Contact this candidate